Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

Inclusion Criteria: * Aged 50-75 years; * Clinical diagnosis is consistent with the definition of late dry AMD in the age-related eye disease study (AREDS), with one or more \>250 um geographic atrophy in the fovea; * Clinical diagnosis is wet AMD, but no obvious efficacy after conventional treatment; * The BCVA of the target eye will be 0.05 to 0.3; * Voluntary as test subjects, informed consent, regular follow-up on time. Exclusion Criteria: * One-eyed subjects; * Macular atrophy caused by other diseases in addition to AMD; * Suffer from retinitis pigmentosa, choroidal retinitis, central serous choroiditis, diabetic retinopathy, or other retinal vascular and degenerative diseases besides AMD; * Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy, and other ocular histories; * Other intraocular surgery histories besides cataract surgery; * Combined with severe systemic diseases, such as heart failure, liver disease, renal insufficiency, cor pulmonale, COPD in the previous 12 months; * Combined with severe infectious diseases, such as HIV, HBV, HCV, syphilis, tuberculosis, etc; * Abnormal blood coagulation function or other laboratory tests; * If female and of childbearing potential, pregnant, breastfeeding, or planning to become pregnant through the study; * If male, refuse to use barrier and spermicide contraception during the study; * Malignant tumor and history of malignancy; * Any immune deficiency; * Allergy to tacrolimus or other macrolides; * Any immune deficiency; * Use glucocorticoids, immunosuppressive drugs, or antipsychotic drugs in the previous 3 months; * Use anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days; * A history of addiction to alcoholism or prohibited drugs; * Be participating in other intervention clinical trials or receiving other study medications; * Poor compliance, difficulty to complete the study, or refusal to informed consent; * Some other situations which might increase the risks of the subjects or interfere with clinical trials, such as mental disorders, cognitive dysfunction, etc.